MediWound Ltd. (MDWD)
NGM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 5.4M | 1.9M | 1.5M | 3.1M |
| Gross Profit | 896K | 278K | 323K | 337K |
| Operating Income | (6.5M) | (7.8M) | (8.0M) | (9.5M) |
| Net Income | (2.7M) | (7.2M) | (3.0M) | (7.4M) |
| Diluted EPS | $-0.24 | $-0.56 | $-0.23 | $-0.77 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 26.5M | 18.7M | 20.2M | 17.0M |
| Gross Profit | 13.2M | 3.6M | 2.6M | 3.3M |
| Operating Income | (7.7M) | (15.5M) | (19.4M) | (25.3M) |
| Net Income | (19.6M) | (6.7M) | (30.2M) | (23.9M) |
| Diluted EPS | $-3.93 | $-0.75 | $-3.03 | $-2.10 |